Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

RegeneCure Starts Worldwide Veterinary Distribution of BoneCure Membrane Implant

Published: Monday, August 12, 2013
Last Updated: Monday, August 12, 2013
Bookmark and Share
Acceleration of fracture healing and carpal arthrodesis.

RegeneCure Ltd. has announced that the company has started to distribute its BoneCure® Membrane product to the veterinary market around the world.

The distribution follows the successful results of a recent clinical study in several EC countries and Israel. BoneCure Membrane was used by European Veterinary Surgeons in pets for the following indications: non-union, large bone gaps, arthrodesis and severe fractures.

The study showed that the healing time was about 40 percent quicker than normally observed using current Standard of Care therapies.

"Based on the outstanding safety and efficacy results of our clinical and pre-clinical studies, we expect BoneCure to enable veterinary surgeons to treat a larger number of severe fracture types and to significantly reduce the healing time and complication rate," said Moshe Tzabari, CEO of RegeneCure.

Distribution with dealers is now underway throughout Europe, Asia, Australia and the United States.

The use of the BoneCure Membrane for carpal arthrodesis is a major breakthrough in the surgery of companion animals that offers many advantages over the traditional “Gold Standard” procedure of harvesting an autogenous bone graft.

This procedure, described at the BoneCure website, prevents patient morbidity and pain, reduces the risks of infection and fracture at the donor site, saves operating time and eliminates the need for a second incision.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!